Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience

Annals of Oncology : Official Journal of the European Society for Medical Oncology
J RodriguezEulogio Conde

Abstract

Here we evaluate the results of high-dose chemotherapy and autologous stem-cell transplantation (HDC/ASCT) in 114 patients included in the GEL/TAMO registry between January 1990 and December 1999 with diffuse large B-cell lymphoma who failed to achieve complete remission (CR) with front-line conventional chemotherapy. Sixty-eight per cent had a partial response (PR) and 32% failed to respond to front-line therapy. At transplant, 35% were chemoresistant and 29% had two to three adjusted International Prognostic Index (a-IPI) risk factors. After HDC/ASCT, 57 (54%) of 105 patients evaluable for response achieved a CR, 16 (15%) a PR and 32 (30%) failed. Nine patients were not assessed for response because of early death due to toxicity. With a median follow-up of 29 months for alive patients, the survival at 5 years is 43%, with a disease-free survival for complete responders of 63%. The lethal toxicity was 8%. Multivariate analysis revealed a-IPI and chemoresistance to be predicting factors. Our results show that one-third of patients who do not obtain a CR to front-line chemotherapy may be cured of their disease with HDC/ASCT. However, most chemoresistant patients pretransplant failed this therapy. For this population, as well as...Continue Reading

Citations

Aug 19, 2008·Current Oncology Reports·Vaishalee Padgaonkar Kenkre, Sonali M Smith
Jul 9, 2008·Nature Clinical Practice. Oncology·Luciano Wannesson, Emanuele Zucca
Jun 2, 2005·Current Opinion in Hematology·Bertrand Coiffier
Mar 26, 2014·South Asian Journal of Cancer·Lalit S Raut, Prantar P Chakrabarti
May 3, 2008·Leukemia & Lymphoma·José RodríguezMiguel Piris
May 20, 2016·British Journal of Haematology·Sridhar ChagantiUNKNOWN British Committee for Standards in Haematology
Jun 3, 2004·The Lancet Oncology·Bryan T HennessyPeter A Daly
Jan 1, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Peter Dreger, Ginna G Laport
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradford S HoppeJoachim Yahalom
Jan 3, 2009·The Korean Journal of Internal Medicine·Ock Bae KoCheolwon Suh
Jun 12, 2009·Cancer·Cristina RobledoUNKNOWN Spanish Lymphoma/ Autologous Bone Marrow Transplant Study Group (GEL-TAMO)
Feb 1, 2009·Expert Review of Hematology·Xavier Poiré, Koen van Besien
Oct 8, 2005·Blood·Mujahid A RizviSteven T Rosen
Jun 15, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Andrew D ZelenetzHema Sundar
Jul 27, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Denise M OlianskyTheresa Hahn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.